People living with HIV face a cancer risk that is several times higher than the general population’s, and managing both conditions simultaneously creates medical challenges that neither disease alone would present. A large Italian cohort study found that HIV-positive individuals had roughly four times the overall cancer risk compared to the general population, with certain virus-linked cancers showing an even steeper increase.1PubMed. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009 The reasons for this overlap go well beyond a weakened immune system, and the treatment landscape has shifted dramatically since the introduction of effective antiretroviral therapy. Still, the combination of HIV and cancer remains one of the more complicated scenarios in modern medicine.
Why HIV Makes Cancer More Likely
A healthy immune system does more than fight infections. It also patrols the body for abnormal cells and destroys them before they can grow into tumors. HIV progressively damages this surveillance system by depleting CD4 T cells, the coordinators of immune defense. When CD4 counts drop low enough, certain cancers become far more probable. Lower CD4 counts (below about 200 cells per microliter) have been identified as a risk factor for both the cancers that officially define AIDS and many that do not.2PubMed Central. The Trends and Risk Factors of AIDS-Defining Cancers and Non-AIDS-Defining Cancers in Adults Living with and without HIV: A Narrative Review
But immune suppression is only part of the story. HIV also creates a state of chronic immune activation and inflammation, even in people on effective treatment whose virus is well controlled. This persistent inflammation can damage DNA in surrounding cells and promote the kind of unchecked cell growth that leads to tumors. Research has also explored whether HIV proteins themselves may have direct effects on cell behavior that favor cancer development, though the immune dysfunction pathway remains the dominant explanation.
AIDS-Defining Cancers Versus the Rest
Doctors split HIV-related cancers into two broad categories. Three cancers are considered “AIDS-defining,” meaning their appearance in someone with HIV signals advanced immune collapse: Kaposi sarcoma, certain types of non-Hodgkin lymphoma, and invasive cervical cancer. These three are all caused by viruses that exploit the immune gaps created by HIV. Kaposi sarcoma is driven by a herpesvirus called KSHV, which infects cells and triggers abnormal blood vessel growth.3PubMed Central. Molecular Mechanisms of Kaposi Sarcoma Development Non-Hodgkin lymphoma is closely tied to Epstein-Barr virus, a pathogen that infects the vast majority of adults worldwide but only rarely causes cancer when the immune system cannot keep it in check.4PubMed Central. How Epstein Barr Virus Causes Lymphomas Cervical cancer is linked to human papillomavirus (HPV), which persists more aggressively in women with HIV.
Everything else falls under “non-AIDS-defining cancers,” or NADCs. This second group has become the bigger concern in wealthier countries where antiretroviral therapy is widely available. A narrative review of multiple studies found that in high-income countries, NADCs now outnumber AIDS-defining cancers, while the reverse tends to hold in lower-income settings where treatment access is more limited.5PubMed Central. The Trends and Risk Factors of AIDS-Defining Cancers and Non-AIDS-Defining Cancers in Adults Living with and without HIV: A Narrative Review NADCs include lung cancer, liver cancer, anal cancer, Hodgkin lymphoma, and many common cancers that occur in the general population too. The Italian cohort data is helpful here: the excess risk for virus-linked NADCs like Hodgkin lymphoma was about twelve times that of the general population, while cancers with no viral connection carried a much smaller excess risk.6PubMed. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009
The Viral Co-Infection Problem
A key reason HIV raises cancer risk so sharply is that it rarely travels alone. People living with HIV are more likely to also carry other cancer-causing viruses, partly because of shared transmission routes and partly because a weakened immune system cannot suppress those viruses effectively.
Hepatitis B and C are prime examples. In a study of liver cancer cases among people with HIV in Texas, about a quarter had hepatitis B, roughly 60% had hepatitis C, and about 14% carried both hepatitis viruses alongside HIV.7JNCI: Journal of the National Cancer Institute. Risk of hepatocellular carcinoma in people with HIV in the United States, 2001-2019 Only about 14% of cases had no hepatitis infection at all. Co-infection with HIV and hepatitis B speeds up liver damage, pushing patients toward cirrhosis and liver cancer faster and at younger ages than hepatitis B alone would.8PubMed Central. Hepatocellular carcinoma in Hepatitis B and Human Immunodeficiency Virus coinfection in Africa: a focus on surveillance HIV worsens every stage of hepatitis B: it leads to higher viral loads, lower rates of the body clearing the infection naturally, more cirrhosis, and more liver-related deaths.9PubMed. Hepatitis B and human immunodeficiency virus coinfection
HPV is another major player. The link between HPV and HIV runs in both directions: having one raises the risk of acquiring the other. Anal cancer, while rare in the general population (accounting for about half a percent of new cancer cases in the United States), is dramatically more common among people with HIV, particularly men who have sex with men.10PubMed Central. HIV-Associated Anal Cancer
How Antiretroviral Therapy Changed the Picture
The introduction of effective combination antiretroviral therapy in the mid-1990s transformed the cancer landscape for people with HIV. A 20-year cohort study tracked cancer rates across four time periods and found that AIDS-defining cancers dropped sharply once effective treatment became available, falling from about 14 cases per 1,000 person-years in the late pre-treatment era to under 3 per 1,000 in the later treatment period. Non-AIDS-defining cancers, however, moved in the opposite direction, rising from about 3 to nearly 7 per 1,000 person-years across the same span.11PubMed Central. Trends in the Incidence of Cancers among HIV-Infected Persons and the Impact of Antiretroviral Therapy: A 20-Year Cohort Study
That rise in non-AIDS-defining cancers reflects a counterintuitive success story: people with HIV now live long enough to develop the cancers that come with aging, smoking, and other lifestyle factors. A later large-scale analysis covering 1997 through 2012 found that after adjusting for the changing age and demographics of the HIV population, overall cancer rates actually fell by about 25%, and AIDS-defining cancers dropped by 55%.12PubMed Central. Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997–2012 The risk gap between people with HIV and the general population has been closing, though it has not disappeared.
Each additional year on antiretroviral therapy lowers the risk of AIDS-defining cancers further. One study estimated a 39% reduction in risk for every year of treatment.13PubMed Central. Exposure to Antiretroviral Therapy and Risk of Cancer in HIV-infected Persons For non-AIDS-defining cancers, though, the relationship is less straightforward. Duration of treatment did not significantly change the overall risk of those cancers, with one exception: longer use of protease inhibitors was linked to a slightly higher risk of anal cancer specifically.
When Immune Recovery Backfires
One of the more unsettling complications of starting HIV treatment is a phenomenon called immune reconstitution inflammatory syndrome, or IRIS. As the immune system recovers, it can overreact to infections or conditions that were present but dormant. In the context of cancer, this most commonly involves Kaposi sarcoma. A person who starts antiretroviral therapy may see a new Kaposi sarcoma lesion appear (called “unmasking” IRIS) or a pre-existing lesion suddenly worsen (called “paradoxical” IRIS), anywhere from a few days to six months after beginning treatment.14PubMed Central. Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma In severe cases, Kaposi sarcoma-IRIS can involve internal organs. One reported case described visceral disease with fluid around the heart developing shortly after a young man with advanced, untreated HIV started therapy for the first time.15PubMed Central. Kaposi Sarcoma-Associated Immune Reconstitution Inflammatory Syndrome (KS-IRIS) in Advanced HIV: Challenges in Managing Visceral Disease With Pericardial Involvement
This creates a genuine dilemma. Antiretroviral therapy is essential for long-term survival and cancer prevention, but in the short term, beginning treatment can temporarily make a cancer-related complication worse. Clinicians have to weigh the timing carefully, sometimes delaying treatment or adding cancer-directed therapy alongside antiretrovirals when they suspect this reaction is likely.
Treating Cancer When Someone Also Has HIV
Giving chemotherapy to a person with HIV introduces complications that go beyond what either condition demands on its own. The most immediate concern is drug interactions. Many older classes of antiretroviral drugs, particularly protease inhibitors and non-nucleoside reverse transcriptase inhibitors, are processed by the same liver enzyme system that breaks down a wide range of chemotherapy agents.16PubMed. Interactions between antiretrovirals and antineoplastic drug therapy When both types of drug compete for the same metabolic pathway, the result can be too much of one drug (leading to dangerous side effects) or too little (reducing the drug’s effectiveness). A recent review highlighted protease inhibitors and NNRTIs as the classes most prone to these clashes.17PubMed. Drug-drug interactions in HIV-infected patients receiving chemotherapy Despite this being a well-known problem, there is limited formal guidance on exactly how to adjust doses when combining these drugs.18PubMed Central. Pharmacotherapy in cancer patients with HIV/AIDS
In practice, many oncologists switch patients to integrase inhibitor-based antiretroviral regimens before starting chemotherapy, because integrase inhibitors cause fewer drug interactions. But this swap is not always simple, and it requires close coordination between HIV specialists and oncologists.
Chemotherapy also hammers the immune system in ways that are especially dangerous for someone whose immune function is already compromised. A study of nearly 200 people with HIV who received chemotherapy or radiation found that treatment dropped CD4 counts by about 200 cells in those who started with relatively healthy counts above 500.19JAMA Oncology. Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the Antiretroviral Therapy Era On the positive side, the treatment did not worsen HIV viral load, suggesting that antiretroviral therapy continued to work even as the immune cell numbers dropped. Low CD4 counts are themselves a risk factor for dangerous infections during chemotherapy: in cancer patients broadly (not just those with HIV), a CD4 count below 450 nearly tripled the odds of developing febrile neutropenia, a potentially life-threatening complication, and raised the odds of early death roughly sevenfold.20PubMed. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer
The specific antiretroviral regimen matters too. In a study of people with HIV and non-small cell lung cancer, use of protease inhibitors was linked to about five times the odds of severe blood-related toxicity from chemotherapy.21Journal of Thoracic Oncology. Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer: Survival and Toxicity of Antineoplastic Chemotherapy in a Cohort Study Findings like these reinforce why choosing the right HIV medication combination becomes a cancer-treatment decision as much as an infectious-disease one.
Immunotherapy and the Clinical Trial Gap
Immune checkpoint inhibitors have been among the most significant advances in cancer treatment over the past decade. These drugs work by releasing the brakes on the immune system so it can attack tumors. That mechanism raises an obvious question for people with HIV: if your immune system is already compromised, can these drugs still work? And could revving up the immune system cause problems with a virus that targets immune cells?
Early evidence suggests that checkpoint inhibitors can be both safe and effective in people with well-controlled HIV. A French prospective cohort study found that the rate of serious immune-related side effects was in a range similar to that seen in HIV-negative patients overall, though certain subgroups faced higher risk. People with CD4 counts below 200 had about four times the rate of severe side effects, and those with a longer history of HIV infection also faced elevated risk.22PubMed Central. Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study
Despite this growing evidence, most checkpoint inhibitor trials still shut the door on people with HIV. An analysis of more than 800 clinical trials from 2019 and 2020 found that nearly three-quarters excluded HIV-positive participants outright. Only about 19% either included them or did not specify.23Scientific Reports. Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials This exclusion rate had not improved compared to 2014, even as real-world data mounted showing that these treatments could work in people with HIV. The result is a feedback loop: without large trial data, doctors hesitate to prescribe the drugs; without prescriptions, the evidence base stays thin; and the exclusion criteria perpetuate themselves.
Worse Outcomes, Even in the Treatment Era
Having HIV alongside cancer still carries a survival penalty, even with modern antiretroviral therapy. In Uganda, where many cancers are diagnosed at later stages, HIV-positive cancer patients had more than double the risk of dying in the year following diagnosis compared to HIV-negative cancer patients, and this held for cancers caused by infections and those that were not.24PubMed Central. Contribution of HIV infection to mortality among cancer patients in Uganda
In the United States, the picture is somewhat less stark but still concerning. Among older adults with cancer, those who were HIV-positive had significantly higher overall mortality across several common cancer types. For colorectal cancer, the mortality risk was about 73% higher; for prostate cancer, about 58% higher; and for breast cancer, about 50% higher compared to HIV-negative patients with the same cancers.25JAMA Oncology. HIV Infection, Cancer Treatment Regimens, and Cancer Outcomes Among Elderly Adults in the United States For women with regional-stage breast cancer specifically, HIV was associated with nearly three times the risk of dying from the cancer itself. These elevated risks likely reflect a mix of factors: immune suppression, more aggressive cancer behavior, treatment complications, and possibly less aggressive treatment being offered to people perceived as too fragile.
Cancers in people with HIV do tend to present differently. They are often diagnosed at a more advanced stage and behave more aggressively, regardless of whether they are AIDS-defining or not.26PubMed. AIDS-related malignancies: state of the art and therapeutic challenges This is partly about biology and partly about gaps in screening and healthcare access.
Primary CNS Lymphoma as a Case Study
Primary central nervous system lymphoma illustrates how HIV can transform a rare cancer into a clinical emergency. In the general population, this brain tumor is uncommon. In people with advanced HIV, the incidence has been estimated at several thousand times higher.27PubMed. AIDS primary central nervous system lymphoma These tumors are B-cell malignancies consistently tied to Epstein-Barr virus, and they appear when the immune system is severely depleted, typically late in the course of untreated or poorly controlled infection.
Diagnosing this cancer in someone with HIV is tricky because the brain lesions look similar on imaging to toxoplasmosis, a parasitic infection that is also common in advanced HIV. MRI characteristics, testing cerebrospinal fluid for Epstein-Barr virus DNA, and specialized brain scans all help distinguish the two, but a brain biopsy often remains the only way to be certain.28PubMed. Primary CNS lymphoma in HIV infection The preferred treatment is antiretroviral therapy combined with high-dose methotrexate-based chemotherapy, a regimen that has improved outcomes significantly compared to the era before effective HIV treatment, when most patients died within months of diagnosis.
Children With HIV and Cancer
Children living with HIV face their own cancer burden, though the specific patterns differ somewhat from adults. In a South African study linking pediatric HIV treatment programs with oncology centers, the overall cancer incidence among children with HIV was 82 per 100,000 person-years, with Kaposi sarcoma and non-Hodgkin lymphoma being the most frequent. Children who started antiretroviral therapy had a 70% lower risk of developing cancer compared to those who did not, underscoring how critical early treatment is in this population.29PubMed Central. HIV-associated malignancies in children Severe immune suppression and older age at the time of starting treatment were both associated with higher cancer risk, meaning that delays in diagnosing or treating a child’s HIV infection carry consequences beyond the infection itself.
Screening and the Access Gap
Given the elevated cancer risk, you might expect that people with HIV would receive more intensive cancer screening. In practice, screening adherence in this population is inconsistent, and the evidence base for how screening guidelines should differ is still thin. Current guidance recommends that people with HIV follow standard age-appropriate cancer screening, with added attention to anal cancer screening (particularly for men who have sex with men), cervical cancer screening, and liver cancer surveillance for those with hepatitis co-infection. But research on the safety and effectiveness of screening specifically in people living with HIV remains a work in progress.30PubMed Central. Screening for Cancer in Persons Living with HIV Infection
The global dimension of this gap is significant. In sub-Saharan Africa, where the HIV burden is heaviest, cancers tend to present at later stages regardless of HIV status, and adding HIV to the picture worsens outcomes further. Breast cancer in sub-Saharan Africa, for instance, is diagnosed at younger ages and at more advanced stages than in wealthier countries.31PubMed Central. Breast Cancer and HIV in Sub-Saharan Africa: A Complex Relationship In regions where both HIV and viral hepatitis are common, the absence of routine liver cancer surveillance for co-infected patients represents a missed opportunity. The research consistently identifies aging and longer duration of HIV infection as risk factors for developing cancer, which means that as people with HIV worldwide live longer thanks to treatment, the demand for cancer screening and treatment will only grow.32PubMed Central. The Trends and Risk Factors of AIDS-Defining Cancers and Non-AIDS-Defining Cancers in Adults Living with and without HIV: A Narrative Review